KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 50 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $101,115 | +7.0% | 10,500 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $94,500 | -41.4% | 10,500 | -48.8% | 0.00% | -50.0% |
| Q1 2023 | $161,130 | -65.1% | 20,500 | -66.1% | 0.00% | -63.6% |
| Q1 2020 | $462,000 | -57.1% | 60,400 | 0.0% | 0.01% | -21.4% |
| Q4 2019 | $1,076,000 | -37.3% | 60,400 | +0.7% | 0.01% | -33.3% |
| Q1 2019 | $1,717,000 | +44.9% | 60,000 | 0.0% | 0.02% | +31.2% |
| Q4 2018 | $1,185,000 | +30.7% | 60,000 | +46.3% | 0.02% | +77.8% |
| Q3 2018 | $907,000 | +172.4% | 41,000 | 0.0% | 0.01% | +200.0% |
| Q2 2018 | $333,000 | -14.4% | 41,000 | 0.0% | 0.00% | -25.0% |
| Q1 2018 | $389,000 | – | 41,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |